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Background: Nano drugs have attracted increased attention due to their unique mode of action that offers
tumor-inhibiting effects. Therefore, we have previously explored functionalized and drug-loaded graphene-gold
nanocomposites that induced cancer cell apoptosis.
Results: In the present study, we developed a combination of monoclonal P-glycoprotein (P-gp) antibodies,
folic acid (FA) and miR-122-loaded gold nanoparticles on graphene nanocomposites (GGMPN), which promoted
drug-resistant HepG2 cell apoptosis with drug targeting and controlled release properties. We also investigated
related apoptosis proteins and apoptosis signal pathways by GGMPN treatment in vitro and in vivo. Moreover,
we further demonstrated the inhibition of tumor growth and the apoptosis-inducing effect by means of
GGMPN with a semiconductor laser in a xenograft tumor model.
Conclusion: In conclusion, our results collectively suggested that GGMPN could serve as a novel therapeutic
approach to control tumor cell apoptosis and growth.
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Since its emergence, nanotechnology has been used in
the medical field. Scientists foresee that nanotechnology
has great potential in the research of cancer therapy devel-
opment. Therefore, making excellent nano-material drugs
with high drug loading, high targeting ability, controlled
release capabilities, low toxicity, and tumor imaging func-
tionality appears to be highly necessary [1,2].
One important component of miR-122-loaded gold
nanoparticles on graphene nanocomposites (GGMPN)
in this study was miRs, which were discovered in recent
years as a class of 18–24 nucleotide non-coding small
molecule RNA [3]. They are involved in life activities* Correspondence: august555482@hotmail.com; nyhe1958@163.com;
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unless otherwise stated.such as ontogeny regulation, cell proliferation, apop-
tosis and differentiation through complete or incomplete
pairing of the 3′UTR, targeting gene mRNA degradation
or inhibiting its translation. Various miRs related to the
regulatory pathways of hepatoma cells are gradually being
discovered. Many researchers have focused on differential
miR expression in hepatoma cells. Expression of miR-122
is down-regulated in many hepatoma cells. As a tumor
marker, miR-122 is involved in the regulation of the trans-
fer of cancer cells in the liver and is significantly reduced
or absent in liver intrahepatic metastasis. In the majority
of liver cancer cells, miR-122 has low expression, and the
expression level of miR-122 in the adjacent tissues is rela-
tively high. There are differences between the expression
of tumor cells and that of normal cells. The lower expres-
sion in high metastatic liver cancer cells in comparison
with normal cells opens up the potential transport func-
tionality for drug delivery [4-6].
Other important characteristics of GGMPN include
the following: the gold nanoparticles can easily absorbhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the chances of eliciting an immune response; the toxicity
of nanomaterials is relatively low; they are not genotoxic
because of their non-viral vectors; and specific mole-
cules (such as the intracellular molecule GSH) can sub-
stitute for nucleic acid in certain concentrations [7]. The
gold-gene nanoparticle vector is usually an amphiphilic
substance (positive and negative electrical attraction)
formed on the basis of a nano-polymer with the core-shell
structure of RNA genetic drugs (miR-122). Folic acid (FA)
receptor expression is highly overexpressed in cancers
of epithelial origin [8]. The FA is loaded on the gold
nanoparticles to provide a targeting function. The ad-
vantage of the gold gene vector is that with the effect
of GSH, it can achieve controlled release of the nucleic
acid, which is preferably more controllable than viral vec-
tors and liposomes.
Graphene is characterized by its large specific surface
area and can be fixed with a variety of substances, in-
cluding antibody molecules, fluorescent molecules, and
drugs (in this study, the P-gp antibody bound to gra-
phene will play the role of targeting drug-resistant can-
cer cells) [9]. In addition, the size of graphene affects its
role as a drug carrier and the effectiveness of the drug
loaded on it. With regards to the selection aspect of the
graphene, it should be in a range of more than 100 nm
to ensure successful loading of the nano-drug onto it
and to prevent it from being easily engulfed by phago-
cytic cells in the body. Nano-drugs can also make use of
the enhanced permeability and retention (EPR) effect to
locate tumor tissue [10-13].
As mentioned above, after the gold particles and miR-
122 form a composite, the composite adheres onto the
graphene that affects drug-resistant cancer cells (gold
particles may be incorporated in the graphene). Chemo-
therapy is an important treatment method for liver can-
cer [14]. Most liver cancer patients often suffer from
ineffective chemotherapy or from effective to gradually
ineffective chemotherapy due to the multidrug resistance
of cells [15]. Multidrug resistance occurs when tumor
cells are exposed to certain anticancer drugs and evolve
drug resistance; they have cross-resistance to other
drugs with different structures and functions [16]. The
mechanism of multidrug resistance formation is very
complex, and the increased expression of the cell mem-
brane P-gp and increased activity of GSH-transferase are
two important factors [17]. The aim of this interdiscip-
linary study is to investigate how to use miR-122, the
P-gp antibody and FA for cancer targeting, tumor im-
aging, and photo-thermal therapy. Size, surface charge,
hydrophobicity and other surface properties will be used
to enhance the killing of cancer cells by using GGMPN
with a semiconductor laser. Furthermore, the toxicity
profiles of the GGMPN on red blood cell (RBC) hemolysiswill be explored. Finally, the mechanisms of GGMPN-
induced apoptosis and cytotoxicity were also investi-
gated [18,19].
Methods
Cells, animals and chemicals
The animal studies were approved by the institutional ani-
mal care and committee of Nanjing Medical University.
The female nude mice (6 weeks old) were purchased from
the Animal Feeding Farm of the National Institute for
the Control of Pharmaceutical and Biological Products
(Beijing, China). All mice were housed in the animal
facility, and the animal experiments were conducted
following the guidelines of the Animal Research Ethics
Board of Nanjing Medical University. The animals were
kept in the facility with free access to food and water. The
adriamycin-resistant HepG2 cell line was purchased from
the Institute of Biochemistry and Cell Biology, Shanghai
Institutes for Biological Sciences, Chinese Academy
of Sciences (Shanghai, China) and was cultured in RPMI
1640 supplemented with 10% FBS (GIBCO) and peni-
cillin (100 U/mL)/streptomycin (100 mg/mL) at 37°C
in a 5% CO2 and water-saturated atmosphere. MiR-122
was synthesized from GenePharma Biotechnology
(Institute of Biochemistry and Cell Biology, Shanghai
Institutes for Biological Sciences, Chinese Academy of
Sciences).
P-gp antibody-graphene oxide synthesis and
characterization
Graphene oxide synthesis and collection: 1 g of graphene
and 50 g of sodium chloride were milled together for
10 mins, and the polish was dissolved in water and fil-
tered. The filtration residue was oxidized with 23 mL
H2SO4 (98%) and stirred for 8 h. Then, 3 g of KMnO4 was
gradually added to the above mixture, and the reaction
temperature was maintained at 20°C. After stirring the
mixture at 38°C for 30 min and then stirring again
for 45 min at 70°C, 46 mL of water was added to the
above-mentioned mixture and was heated to 98°C for
30 min. Then, 140 mL of water and 10 mL of H2O2
(30%) was gradually added to the above mixture. After
sufficient reaction product was recovered by filtration, the
filtrate was dissolved in 10 mL HCl (5%). Gradient
centrifugation was used on 1 mL of the above graphene
(1.5 mg/mL) to separate it by size and type. The following
centrifugation conditions were used, sequentially: 2 h,
10,000 rpm/min; 2 h, 20000 rpm/min; 2 h, 30,000 rpm/
min; 2 h, 40,000 rpm/min; and 2 h, 50,000 rpm/min. After
centrifugation, the sample was dried at room temperature,
and a JEM-2100 transmission electron microscope (TEM)
was used to observe the morphology of the sample. The
hydroxyl group along the 500 nm side of the graphene
oxide was replaced with a carboxylic acid. Then, 5 mL of
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(ultrasound 1 h) and 1.0 mL chloroacetic acid (Cl-CH2-
COOH) were added to the above solution and placed
in ultrasound for 2 h. P-gp antibody (1 mg/mL) was
added to the above-described oxidation graphene re-
action system (v/v, 1:10) to react overnight. The prod-
uct was dried under vacuum at room temperature, and
protein electrophoresis analysis was performed. The
antibody remaining in supernatant was checked using
a Protein Assay kit (Thermo Scientific, USA). The same
antibody without adsorption on GGMPN was used as
the control.MiR-122-gold nanoparticles synthesis and control relase
analysis
Briefly, 0.3 mL freshly prepared sodium borohydride
(0.08%), 1 mL CTAB (2.15%) and 0.32 mL chloroauric acid
(1%) were added dropwise to 30 mL of a FA (1 mg/mL)
solution, which was stirred for 20 min at room temperature.
Gold nanoparticles mixed with 0.5 mL miR-122 (0.001 mg/
mL) were stirred for 0.5 h, and the gold nanoparticles were
recovered by centrifugation. The OD value of the super-
natant was used to quantify the amount of miR-122
loaded. The same amount of miR-122 of the gold nano-
particles was loaded into the wells of an agarose gel to
perform electrophoresis to detect GSH for miR-122 in the
sustained-release experiment. For the well without GSH
added, no nucleic acid showed bands. Similarly, we used
miR-122 with added AO (acridine orange), which showed
a fluorescence intensity change. After the disappear-
ance of fluorescence, gold nanoparticles were added, and
miR-122 was adsorbed onto the gold nanoparticles. Add-
ing GSH (GSH replaced miR-122) enabled miR-122 to
recombine with the AO. This experiment provided fur-
ther evidence showing that GSH could control the release
of miR-122.
Preparation and characterization of GGMPN compos-
ites: 1 mL of P-g antibody-graphene oxide (1 mg/mL)
was added to the chitosan solution (1% acetic acid,
pH 5.0) and sonicated for 2 h. The final product was
then mixed with 0.5 mL (0.001 mg/mL) of the miR-122-
gold nanoparticles and stirred overnight. The reactant
from vacuum drying was GGMPN, and a JEM-2100 trans-
mission electron microscope was used for characterization
of the GGMPN morphology.GGMPN biocompatibility assay
A SD rat (4 weeks, orbital vein blood) RBC hemolysis
experiment was used to test the blood compatibility of
GGMPN. Blood was collected in heparinized tubes and
centrifuged for 10 min at 1,000 g using a cold centrifuge
at 4°C. Samples were washed three times with PBS. The
extent of hemolysis was determined under a microscope.HepG2 membrane permeability and intracellular miR-122
accumulation assay
The permeability of the adriamycin-resistant HepG2
(folate receptor FR(+)) cell membrane was measured by
lactate dehydrogenase (LDH CytoTox 96 assay) treated
with GGMPN. The intracellular fluorescence intensity of
red fluorescence-labeled miR-122 of was used to detect
and quantify the accumulation of miR-122 in cancer
cells with confocal fluorescence microscopy.
SEM analysis of morphological images of HepG2 cells
HepG2 cells were seeded on top of cover glass slips;
GGMPN was then administered to these HepG2 cells.
After 1 h of incubation, the cells were trypsinized and
fixed using 2.5% glutaraldehyde overnight. The treated
cells were washed with PBS for 5 min, after which they
were washed again with 30%, 50%, 70%, 80%, 90%, 95%
and 100% ethanol before being carefully dried for SEM
experiments.
TEM analysis of cellular distribution of gold nanoparticles
Drug resistant HepG2 cells were treated with GGMPN,
washed with PBS, and then fixed in 2.5% glutaraldehyde.
Ultrathin sections were cut and mounted on copper grids.
These sections were viewed under a JEOL 1200-EX trans-
mission electron microscope equipped with energy disper-
sive X-ray spectroscopy (EDS). Gold nanoparticles were
identified by EDS analysis, and their sub-cellular distri-
bution was investigated from the transmission electron
micrographs.
MTT assay on cytotoxicity
Drug-resistant HepG2 cells were maintained in RPMI-
1640 medium containing 10% FBS, 100 U/mL of penicil-
lin, and 100 μg/mL of streptomycin at 37°C with 5%
CO2 before being plated in 96-well plates (2 × 10
3 cells/
well). After overnight incubation, various concentrations
of GGMPN treatment were added into specified wells.
After 36 h, a 20 μL MTT solution (5 mg/mL) aliquot
was added to each well. After 4 h of incubation, the
supernatant was removed, and 100 μL of DMSO was
added to each well. The samples were then shaken for
15 min before the optical density (OD) was checked at a
wavelength of 540 nm. All experiments were performed
in triplicate. Relative inhibition of cell growth was calcu-
lated as follows: Cell viability% = ([OD] test/[OD] con-
trol) × 100%.
In vitro GGMPN promote cancer cell apoptosis analysis
Staining detection of DNA fragments and flow cytome-
try apoptosis rate determination was performed on the
HepG2 cells treated with miR-122/Lipofectamine 2000
or GGMPN. Apoptotic DNA extraction of HepG2 cells
was carried out by a Biovision apoptosis DNA ladder
Figure 1 (See legend on next page.)
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Figure 1 Synthesis and characterization of miR-122-loaded graphene-gold composites. A: HRTEM image of miR-122-loaded graphene-gold
composites (Scale bar =20 nm). B: Low magnification image of gold nanoparticles (Scale bar =20 nm). C: Confirmed function of miR-122 release
by GSH through agarose gel electrophoresis assay; 1) 1 mg/L miR-122, 2) 10 mg/L GGMPN, 3) 10 mg/L GGMPN + 2 μM GSH, 4) 10 mg/L GGMPN +
2 mM GSH, 5) 10 mg/L GGMPN+ 10 mM GSH. D: Verified function of miR-122 by GSH through AO fluorescence assay; 1) AO, 2) AO +miR-122, 3) AO+
miR-122 + gold nanoparticles, 4) AO +miR-122 + gold nanoparticles + 2 mM GSH, 5) AO+miR-122 + gold nanoparticle + 10 mM GSH. E: TEM image of
graphene oxide (Scale bar =50 nm). F: TEM image of GGMPN nanocomplexes (Scale bar =50 nm). G: Protein electrophoresis analysis of P-gp
antibody. P-gp antibody (lane 1), P-gp antibody-loaded GGMPN (lane 2). H: Quantification of P-gp antibody remaining in solution before
(1) and after 1 h (2) or 24 h (3) exposure to graphene oxide.
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phoresis analysis.
Western blot analysis: Antibodies against the following
were used: Bcl-w, Caspase 9 (mitochondrial pathway),
Caspase 3, PARP, p38, and JNK MAPK (involved in cell
proliferation and differentiation). The proteins were de-
tected by enhanced chemiluminescence.
Photothermal therapy on HepG2 cells by GGMPN
GGMPN was used for HepG2 in vitro laser hyperther-
mia. The laser irradiation experiment involved choosing
different wavelengths of semiconductor lasers. HepG2
cells were added to the GGMPN solution, exposed to a
power density of 20 W/cm2 of the semiconductor laser
light source and irradiated for 1 min for trypan blue
staining.
GGMPN to target tumor cells image and promote
apoptosis of HepG2 tumor in nude mice
HepG2 tumors in nude mice (in vivo model): HepG2
cells (106 cells in 200 μL DMEM culture) were injected
in a logarithmic growth phase in nude mice and divided
into 3 groups, each consisting of 5 nude mice: the first
group was the saline control group, the second group
was the 1 mg/kg miR-122/Lipofectamine 2000-treated
group, and the third group was the 10 mg/kg GGMPN-
treated group. One week after tumor cell inoculation,
when the tumor had grown to approximately 50 mm3
size, four groups of nude mice were injected in the tail
vein with variety of drugs at 0, 2, 4, 6, 8, 10, 12, 14, 16,
and 18 days. After the first 20 days, when the tumor was
removed and fixed with formalin, the size of the tumor
volume was calculated by the following formula: V = π/
6 × [(A + B)/2]3, where A was the maximum diameter
of the tumor and B was the minimum diameter of
the tumor.
Photothermal therapy experiments in vivo: nude mice
were injected in the tail vein with GGMPN. The tumor
was irradiated with the semiconductor laser light source
10 times for 10 min (every two days). Then, the tumor was
removed, and its final volume was calculated.
For the tumor imaging study, biodistribution activities
were induced to obtain enough activity to acquire theimages. GGMPN was used for confocal microscopy 3D
reconstruction imaging of HepG2 cells, and the detec-
tion of green, yellow, and red separately fluorescently
labeled miR-122-GGMPN in HepG2 cells was carried
out. The animals were anesthetized with pentobarbital
sodium intraperitoneally and were placed on the table
in a side position so that the detector was positioned on
the tumor region of the animal. A small animal model
in vivo imaging instrument (Carestream Multispectral)
was used (Lumina XR).
Apoptosis was achieved by terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL)
detection of DNA fragments. When observed under a
microscope, dark brown cell apoptosis was found in
tumor cells, while blue cells were found in normal tumor
cells. Three slices of each tumor were randomly selected,
and 10 images of each slice were taken for statistical
analysis. Apoptosis in vivo: pictures of nude mouse tumor
tissue were taken, the tumor was lysed, and protein
extracts were used for western blot analysis. The anti-
bodies used included those against Bcl-w, Caspase 9
(mitochondrial pathway), and Caspase 3 to study the rela-
tionship of the signal transduction pathway and tumor
proliferation.Detection of gold nanoparticles in nude mice’ organs
Five mice from each group were sacrificed (carbon di-
oxide euthanasia) at 5 weeks to obtain organs (bone, skin,
muscle, intestine, liver and tumor). The tissue was
digested to measure Au levels. All of the organs were
washed with distilled, deionized water and dried on
paper towels. Samples were dried to constant weights at
105°C. The organs were then ground in an agate mortar
and digested in aqua regia. After appropriate dilution
with double-distilled H2O, the metal concentrations
of the samples were determined by atomic absorption
spectrophotometry.Statistical analysis
Results were presented as Mean ± SD. A t-test was
performed in each group for each time point. A value
of P < 0.05 was considered statistically significant.
Figure 2 (See legend on next page.)
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Figure 2 Biocompatibility assay and TEM image of the cellular distribution of GGMPN. A: Photographs of RBC suspensions in the presence
of various reagents; a) 10 mg/L GGMPN for 1 h, b) 1 mg/L miR-122 (same concentration as loaded on GGMPN) was transfected with Lipofectamine
2000 for 1 h, c) untreated control, d) treated with 10 mg/L GGMPN for 5 h (Scale bar =20 μm). B: Characterization of sub-cellular distribution of gold
nanoparticles by TEM and EDS; a, c) TEM image of gold nanoparticles in tumor cells treated with or without 10 mg/L GGMPN, b, d) EDS analysis of
gold nanoparticles distributed in tumor cells treated with or without 10 mg/L GGMPN ( Scale bar =50 nm). C: a) SEM image of HepG2 cells after
GGMPN treatment (during 1 h); b) SEM image of HepG2 cells transfected with miR-122 (1 mg/L, the same concentration as loaded on GGMNP)
(during 1 h); c) Morphology of HepG2 cells after GGMPN treatments by microscope assays.
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Synthesis and identification of GGMPN
Gold nanoparticles loaded with miR-122, termed GGMPN,
were synthesized and identified using TEM imaging.
We found that the complex of gold nanoparticles and
miR-122 was approximately 20 nm (Figure 1A). How-
ever, the average size of the gold nanoparticles was
approximately 5 nm (Figure 1B). Thus, we speculated
that an abundant amount of miR-122 could be combined
with the gold nanoparticles. We already knew that
some small molecules (e.g., RNA) could be flexibly re-
leased by GSH from the surface of the nanoparticles.
We combined negatively charged miR-122 with positively
charged gold nanoparticles. As shown in Figure 1, the
release reactions between gold nanoparticles and miR-122
could be performed through electrophoresis assays
(Figure 1C). We demonstrated that gold nanoparticles
completely prevented miR-122 from moving to the posi-
tive electrode; thus, the gold nanoparticles/miR-122
remained in the sample well (Figure 1C, lane 2). It could
be observed that the positively charged gold nanoparticles
counteracted the negative charges of miR-122. As ex-
pected, a small amount of miR-122 was detected at
the same site of pure miR-122 (Figure 1C, lane 1) when
the concentration of GSH reached 2 mM (Figure 1C,
lane 4). The mobility of miR-122 completely recovered
when the final concentration of GSH reached 10 mM
(Figure 1C, lane 5). Negatively charged GSH contained
a thiol ligand, which had a stronger affinity to the gold
nanoparticles. Herein, it was established that the addition
of GSH might counteract the positive charge of gold
nanoparticles to some extent by place exchange and re-
sulted in the release of miR-122 from the gold nanoparti-
cles (Figure 1D).
As shown in Figure 1E and F, graphene oxide and
GGMPN nanocomposites (500 nm) were synthesized and
characterized. The TEM image demonstrated a homo-
geneous distribution of gold nanoparticles on the P-gp
antibody-graphene oxide surface with chitosan function-
ality. Moreover, we also illustrated that the P-gp anti-
body could be effectively absorbed by graphene oxide
(Figure 1H) and separated from GGMPN (Figure 1G).
The results suggested that P-gp antibody-graphene oxide
and GSH might play a critical role in combining miR-122
with GGMPN to enhance the targeting of miR-122 tocancer cells. The relevant miR-122 loading efficiency
was further determined by OD analysis, which indicated
that the miR-122 loading onto GGMPN was approxi-
mately 10%.Biocompatibility and cellular distribution analysis of
GGMPN
We next assessed the hemolytic effect of GGMPN in cells
subjected to various treatments. For RBCs (red blood cells)
treated with 10 mg/L GGMPN for 5 h (Figure 2A, d),
there was no hemolysis of RBCs co-cultured with 10 mg/L
GGMPN for 1 h (Figure 2A, a), of those transfected with
miR-122 (Figure 2A, b), or of the untreated control
(Figure 2A, b). Furthermore, it was expected that slight
hemolysis would occur when RBCs were treated with
GGMPN for 5 h (Figure 2A, d). The results showed that
GGMPN had a low hemolytic effect when treated with
cells for 5 h.
We next observed the morphological changes on sub-
HepG2 cells after treatment with or without GGMPN.
TEM characterization showed the typical distribution
of gold nanoparticles in HepG2 cells treated with GGMPN
(Figure 2B, a) compared with the untreated control
(Figure 2B, c). Meanwhile, both dispersive nanoparticles
and clusters of gold nanoparticles were observed in tumor
cells (Figure 2B, a). Additionally, the results (Figure 2B, b)
of EDS analysis remarkably demonstrated gold content
in the cells, which was consistent with the above TEM
study (Figure 2B, a), suggesting that gold nanoparticles
could be readily internalized by cells for drug delivery.
In contrast, the images (Figure 2B, d) from EDS analysis
showed no gold content in HepG2 cells (not treated with
GGMPN). These results suggested that GGMPN was bio-
logically safe and could deliver miR-122 into targeted can-
cer cells.
Based on the above study, bio-imaging of GGMPN or
miR-122 alone in HepG2 cell lines was performed with
a scanning electron microscope (SEM). As shown in
Figure 2C, a, the morphology of HepG2 cells was chan-
ged when treated with GGMPN. The treatment also
caused stronger adsorption of GGMPN on the cell mem-
brane compared with miR-122 transfected with Lipo-
fectamine 2000 (Figure 2C, b). GGMPN induced the
morphological changes in HepG2 cells (Figure 2C, c).
Figure 3 (See legend on next page.)
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Figure 3 Morphological and intracellular miR-122 accumulation assay. A: SEM image of HepG2 cells incubated with 10 mg/L GGMPN (a), or
without treatment (b) for 1 h (Scale bar =3 μm). B: GGMPN delivered miR-122 into resistant HepG2 cells as imaged through laser confocal
fluorescence microscopy; a-c) untreated cells, d-f) cells transfected with red fluorescent-modified miR-122 (1 mg/L, same concentration as
loaded on GGMPN), g-i) cells combined with 10 mg/L GGMPN-loading red fluorescent-modified miR-122 (Scale bar = 50 μm). C: Quantitative assay of
GGMPN on cell membrane permeability based on the CytoTox 96 assays; 1) untreated control, 2) resistant HepG2 cells transfected with miR-122
(1 mg/L, same concentration as loaded on GGMPN), 3) resistant HepG2 cells incubated with 10 m/L GGMPN. D: MTT assay for evaluation of the
growth of cells treated with GGMPN. HepG2 cells were treated with 0.001, 0.01, 0.1, 1, 10, 100, 1000, or 10000 mg/L of GGMPN. *P < 0.05 indicates a
significant difference in comparison to untreated control. E: DNA fragmentation of HepG2 cells after different treatments. Genomic DNA was
isolated from HepG2 cells, which were treated as follows: 5 mg/L GGMPN (lane 1), 2 mg/L GGMPN (lane 2), or 10 mg/L GGMPN (lane 3);
DNA marker (M).
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FA on miR-122 of gold nanoparticles caused more miR-122
adherence with the gold nanoparticles on the surface
of the cell membranes (Figure 3A, a) compared with can-
cer cells (unloaded FA on gold nanoparticles) (Figure 3A, b).
We demonstrated that the miR-122 on the gold nanopar-
ticles could precisely target the cancer cells with the FA
functionality.
Next, we further determined the location of GGMPN
in HepG2 cells with laser confocal fluorescence micros-
copy. For the control cells without treatment, we observed
almost no intracellular fluorescence in the HepG2 cells
(Figure 3B, a,b,c). However, the intracellular fluorescence
in HepG2 cells increased dramatically upon treatment
with GGMPN containing the red fluorescent-modified
miR-122 (Figure 3B, g,h,i) compared with miR-122-
transfected cells (Figure 3B, d,e,f ). The results indicate
that the intracellular content of miR-122 increased after
treatment with GGMPN. These results demonstrated that
GGMPN carrying miR-122 could be effectively taken in
by drug-resistant HepG2 cells. They also showed that
GGMPN had an impact on cell permeability compared
with cells transfected with miR-122 (Figure 3C). More-
over, when increasing the concentration of GGMPN, we
also demonstrated that the growth of HepG2 cells was
strongly suppressed (Figure 3D), and the intensity of frag-
mented chromosomal DNA bands of treated HepG2 cells
became much stronger (Figure 3E).
Analysis of apoptosis in GGMPN treated cells
In order to further determine the apoptotic effect of
GGMPN in HepG2 cells, the AO/EB staining assay
was used. Apoptotic nuclei were identified by their
characteristic features such as chromosomal conden-
sation, with distinct margination and fragmentation
under fluorescence microscopy. In the present study,
we also found that the apoptotic nuclei of HepG2 cells
(Figure 4A (d,h,l), later apoptosis nuclei) treated with
GGMPN for 48 h could be clearly identified by their
distinctively marginated and fragmented appearance
compared with early stage of apoptosis in cells treatedfor 24 h (Figure 4A (b,f,j), early apoptosis nuclei) and
normal dead cells (Figure 4A (c,g,k)). For the control
cells without treatment, cell nuclei were normal, as
shown in Figure 4A (a,e,i).
It was shown using Annexin-V-FITC apoptosis detec-
tion that GGMPN induced a much higher apoptosis rate
in resistant HepG2 cells (Figure 4B, c) than that of cells
transfected with miR-122 (Figure 4B, b) or the untreated
control (Figure 4B, a). Meanwhile, we also found that
the percentage of apoptotic cells was 60.1%, 47.8%, and
5% for those treated with GGMPN, miR-122 and no treat-
ment, respectively (Figure 4B, d). Furthermore, we further
confirmed the apoptosis of cells induced by GGMPN
treatment using a DNA fragmentation assay. When
HepG2 cells were treated with GGMPN, the intensity of
fragmented chromosomal DNA bands (Figure 4C, lane 3)
was much higher than that observed from cells treated
with miR-122 (Figure 4C, lane 2) or the untreated control
(Figure 4C, lane 1).
In order to explore the molecular mechanisms under-
lying the GGMPN-induced DNA fragmentation, we ex-
amined the expression of apoptosis-related proteins in
the cells. As shown in Figure 4D, we found that the pro-
tein level of Bcl-w, which was a target gene of miR-122,
was reduced in HepG2 cells after treatment with GGMPN.
Moreover, the cleaved Caspase 9 signals were much stron-
ger in cells treated with miR-122 (Figure 4D, lane 2) than
in the untreated control cells (Figure 4D, lane 1). The
strongest activation of Caspase 9 occurred after GGMPN
treatment (Figure 4D, lane 3). Similar results were ob-
tained for cleaved Caspase 3 and cleaved PARP because
they are the downstream elements of the Caspase 9 path-
way. The MAPK signal was weaker after GGMPN treat-
ment than after miR-122 treatment as a result of the
drug-resistant nature of the cells (Figure 4D, lanes 3 and
2, respectively). The same trend of protein expression was
not obtained for P38 and JNK. These data suggested that
GGMPN treatment involved the inhibition of activation of
anti-apoptosis proteins and caused apoptosis by activation
of the Caspase-9, Caspase-3 and MAPK pathways in re-
sistant HepG2 cells.
Figure 4 (See legend on next page.)
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Figure 4 Apoptotic assay of HepG2 cells induced by GGMPN. A: HepG2 cells were treated with 10 mg/L GGMPN, and their apoptotic level
was detected by AO/EB staining; (a, e, i) image of normal cells, (b, f, j) image of early apoptotic cells, (c, g, k) normal dead cells, (d, h, l) image
of late apoptotic cells (Scale bar =10 μm). B: Flow cytometric measurement of cellular apoptosis of resistant HepG2 cells treated with various
reagents; a) untreated control, b) transfected cells with miR-122 (1 mg/L, same concentration as loaded on GGMPN), c) treatment of cells with
10 mg/L GGMPN for 36 h, d) quantitative analysis of apoptotic cells after various treatments shown in a), b) and c), *P < 0.05, compared with the
control treatment. C: DNA fragmentation in resistant HepG2 cells after different treatments; 1) untreated cells, 2) transfected cells with miR-122
(1 mg/L, same concentration as loaded on GGMPN), 3) treatment of cells with 10 mg/L GGMPN, 4) DNA marker. D: Western blot analysis of
activated Caspase levels after various treatments; 1) without treatment cells, 2) cells transfected with miR-122, 3) cells treated with GGMPN.
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To further explore the multifunctional anti-cancer effect
of HepG2 cells treated with GGMPN, we probed the
GGMPN with a semiconductor laser to perform a hyper-
thermia experiment. As shown in Figure 5, we found
that HepG2 cells treated with GGMPN were severely dam-
aged at a laser power threshold of 20 W/cm2 for 10 min
(Figure 5A, d) compared with other treatments (Figure 5A,
a,b,c). However, no photo-thermal destruction was ob-
served for HepG2 cells treated with miR-122 (Figure 5A, b).
Quantitative analysis also showed that the percentages of
dyed cells (blue cells) were 2% (control), 3.1% (miR-122
treated), 77.4% (10 mg/L GGMPN at a laser power thresh-
old of 20 W/cm2 for 1 min), and 95.8% (for 10 min)
(Figure 5C).
To further identify the function of GGMPN in vivo, we
established a method to estimate the effect of GGMPN in
tumor tissue (Figure 5D-G). In this experiment, 6-week-
old mice were subcutaneously implanted with 106 HepG2
tumor cells. After 10 days post-implantation, the mice
were divided to 3 groups with 5 mice in each group
(Figure 5D). The mice were intravenously injected with
various reagents every other day. Combined GGMPN with
a 2 W/cm2 power semiconductor laser for 10 min every
two days (Figure 5E, c) effectively reduced the size and
volume (Figure 5D, c) (Figure 5F, 3) of the implanted tu-
mors compared with the untreated group (Figure 5D, a)
(Figure 5F, 1) or the miR-122 treatment group (Figure 5D, b)
(Figure 5F, 2).
We then further examined the effects of treatment
with GGMPN on apoptotic signals. In this experiment,
we examined the expression of apoptosis-related proteins
in mouse-implanted tumors. As shown in Figure 5G, we
found that the protein level of Bcl-w was reduced in mice
tumors after treatment with GGMPN (lane 3) compared
with miR-122 (lane 2) or the untreated group (lane 1).
Moreover, the cleaved Caspase 9 and 3 signals were much
stronger in tumors treated with GGMPN with photother-
mal therapy (lane 3) than with miR-122 (lane 2) or the un-
treated group (lane 1). These results further provided
evidence that GGMPN with photothermal therapy could
reduce the apoptosis and inhibit the growth of tumor
in vivo.Analysis of target tumor cell image in vivo
Finally, we detected the fluorescent effect of GGMPN la-
beled by different fluorescent dyes in vitro and in vivo.
As shown in Figure 6, 3D reconstruction of HepG2 cells
with GGMPN treatment demonstrated a higher intra-
cellular distribution and target function of miR-122
(Figure 6A). Six-week-old nude mice were subcutane-
ously implanted with 106 HepG2 tumor cells that were
treated with labeled GGMPN. We found that the tumors
of mice treated with labeled GGMPN could produce
fluorescence spontaneously (Figure 6B, b and c). We also
found that the percentage of apoptotic cells was 75.9%,
39.7% and 9.1% for treatment with 10 mg/kg GGMPN,
miR-122 (transfected cells with miR-122) and the un-
treated control, respectively (Figure 6C). These results
further indicated that GGMPN was good carrier to effect-
ively deliver miR-122 into cancer cells. Moreover, Au con-
centration in nude mice injected with GGMPN was
significantly higher in tumor tissues than in the other
groups, as shown in Figure 6D.Discussion
As a novel delivery tool, gold nanoparticles (positively
charged) could easily absorb small biological molecules
(FA) and non-coding RNAs (miR-122). The rationale
was that gold nanoparticles, FA and miR-122 were amphi-
philic substances (both positive and negative electrical at-
traction) formed on the core-shell structure of the FA and
miR-122 genetic drugs (Figure 1). Gold nanoparticles-
miR-122 were formed in nanocomposites, which were fur-
ther adhered onto graphene. P-gp antibody combined with
graphene (Figure 1G,H) performed the targeting of drug-
resistant HepG2 cells (Figure 2C). In reality, the size of
the graphene is a factor that affects its functioning as a
drug carrier. If the size of graphene is too large, it will
affect the drug transport in the blood stream. If it is too
small, it will affect the drug loading and be easily phagocy-
tosed. Thus, we concluded that the size of graphene
should be in the range of approximately 500 nm (through
gradient centrifugation) to ensure the graphene drug load-
ing and to avoid phagocytosis by phagocytic cells in vivo.
As mentioned above, the nano-drug size range could use
Figure 5 Photothermal therapy assay of HepG2 cells treated with GGMPN. A: Images of photothermal therapy of cells with various treatments;
a) control experiment, b) transfected with miR-122, c) treated 10 mg/L GGMPN with laser power threshold of 20 W/cm2 for 1 min, d) or 10 min. (Scale
bar = 20 μm). B: Photo of photothermal therapy with semiconductor laser light. C: Quantitative analysis of apoptotic cells after various treatments as
shown in A, * P < 0.05, compared to the control treatment. D: Laser hyperthermia with laser irradiation light for inhibition of tumor growth in HepG2
nude mice with different treatments, a) untreated used as control, b) transfected with miR-122 (1 mg/kg, same concentration as loaded on GGMPN),
c) treated 10 mg/L GGMPN with laser power threshold of 2 W/cm2. E: Photo of tumor irradiated for by laser hyperthermia; a) photo of laser
hyperthermia, b) untreated control, c) tumor irradiated by laser hyperthermia. F: Quantitative analysis of tumor volume after various treatments
as in (D). G: Western blot analysis of apoptosis-related protein in tumors of mice treated as in (D).
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target the tumor.
GSH could control the miR-122 release from the gold
nanoparticles by replacing the function, which allowed the
realization of sustained, controlled release of miR-122 incancer cells. As a result of our study, the concentration of
GSH in erythrocytes was 2 mM, while it was 10 mM in
the resistant HepG2 cells (Figure 1C). FR was highly over-
expressed in the HepG2 cell line that we selected. Due to
the P-gp antibody and FA, the GGMPN could target the
Figure 6 (See legend on next page.)
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Figure 6 Images of tumor cells in vitro and in vivo. A: 3D reconstruction of HepG2 cells treated with 10 mg/L GGMPN with green (a), yellow
(b), and red (c) fluorescence separately to analyze intracellular distribution (Scale bar = 100 μm), image of HepG2 cells treated with GGMPN
labeled with green, yellow and red fluorescence (d). B: Fluorescence image of tumor after intravenous injection of 10 mg/L GGMPN (miR-122
with red fluorescent) solution for 2 h; a) bright mouse image, b) fluorescence intensity scan of xenograft tumor, c) red fluorescence near the
tumor. C: TUNEL staining of HepG2 xenograft tumors after various treatments; 1) untreated control, 2) transfected cells with miR-122, 3) treatment
cells with GGMPN, quantitative analysis of apoptotic rate after various treatments (C). D: Distribution of Au levels in the liver, the brain, the bone,
the muscle, the intestines, and the tumor, respectively. The group numbers for the mouse organs are as follows: (1) bone, (2) skin, (3) muscle, (4)
intestine, (5) liver and (6) tumor.
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by both the membrane FR and the reduced folate carrier
[20,21]. In this study, we targeted cancer cells via two
pathways. As mentioned above, gold nanoparticles loaded
with miR-122 were formed as nanocomposites, and the
nanocomposite was adhered onto graphene to induce the
apoptosis of drug-resistant cancer cells (gold nanopar-
ticles incorporated in the graphene with chitosan ac-
tivity). Therefore, the nanoparticles could enter the cell
by absorbing and puncturing the cancer cell membrane
when miR-122-loaded gold nanoparticles were absorbed
by HepG2 cells (Figure 3A). The GSH effect provided a
potential environment for miR-122 entry into HepG2
cells. In fact, we selected miR-122 instead of chemical
drugs for two reasons: to avoid the high toxicity of chemical
drugs and to attempt to avoid the multi-drug resistance
mechanism of hepatocellular carcinoma in chemotherapy.
HepG2 membrane permeability and intracellular miR-
122 accumulation assays were performed. After GGMPN
treatment, an increase in the intracellular intensity of the
amount of miR-122 was observed in the HepG2 cells. The
results demonstrated that cell membrane permeability
was significantly increased by GGMPN that then induced
the intake of miR-122 in HepG2 cells (Figure 3B). Consist-
ent with this result, gold nanoparticles were also found
in the HepG2 cells by TEM characterization and EDS ana-
lysis (Figure 2B). These results suggested that gold nanopar-
ticles could be readily internalized by cells for drug delivery.
Next, we further investigated the apoptotic effect of
GGMPN on cancer cells by the use of an MTT assay,
nuclei staining, and a DNA fragment assay. The results
demonstrated that GGMPN elicited an anti-proliferative
effect in a dose-dependent manner in HepG2 cells. The ap-
parent IC50 value for GGMPN was estimated as 10 mg/L
for HepG2 cells (Figure 3D). Using AO/EB staining for
apoptotic cells, apoptotic nuclei were identified by their
distinctively marginated and fragmented appearance. The
apoptotic nuclei of HepG2 cells (Figure 4A) at 48 h could
be identified by their distinctively marginated and frag-
mented appearance. For the control cells without treat-
ment, cell nuclei were normal. In effect, this was the
reason why DNA extracting methods were used to pro-
duce apoptosis DNA ladders. Next, it was determined
whether cell growth inhibition was caused by theapoptotic response, and the results in Figure 4B show that
relevant GGMPN induced a much higher cell apoptosis
rate than the untreated control using the Annexin-V-
FITC, PI apoptosis detection method. The apoptosis DNA
ladders were examined by agarose gel electrophoresis.
HepG2 cells were treated with GGMPN, and the intensity
of the apoptosis DNA ladders were much higher than that
observed from untreated cells or those treated with miR-
122. Our observations supported the hypothesis that the
remarkable enhancement of apoptosis was induced by the
synergistic effect of GGMPN. We carried out anti-cancer
research on the GGMPN apoptosis signaling pathway.
According to previous studies, miR-122 could induce
apoptosis through the Bcl-w pathway. However, the under-
lying molecular mechanisms of graphene-gold materials
and miR-122-induced cancer cell apoptosis were still
not very clear. This study highlighted the mechanism of
apoptosis in drug-resistant HepG2 cells by GGMPN treat-
ment. We found that GGMPN treatment activates Bcl-w
and Caspase 9 pathways to induce apoptosis in HepG2
cells. Cleaved Caspase-9 activated Caspase-3, which corre-
lated with the increased cleaved PARP expression after
GGMPN treatments (Figure 4D). Apoptosis DNA ladders
were induced during the cell apoptosis by cleaved PARP
expression.
Analysis of fluorescent bio-images of the tumors indi-
cated that GGMPN enhanced the treated group, and the
image showed features of HepG2 tumors in vivo (Figure 6B).
This was expected to improve target volume consistency
for treatment. The image results also indicated evidence
of photothermal activity. Photothermal activity could de-
posit a sufficient amount of energy into the tissue under
appropriate conditions to raise the temperature above a
certain threshold so that cellular cancer destruction could
occur. The GGMPN-enhanced photothermal killing of
tumor cells by laser had been proven to be effective both
in vitro and in vivo. As shown in Figure 5, cancer cells
treated with GGMPN were destroyed with the laser, and
the growth of the tumor was suppressed. This result was
indeed consistent with the earlier observations regarding
laser treatment for photothermal therapy in vitro. Mean-
while, the possibility of a tumor inhibition effect on cellu-
lar metabolism that increased the apoptosis of tumor cells
was analyzed in vivo. The anticancer effect of GGMPN
Yuan et al. Journal of Nanobiotechnology  (2015) 13:12 Page 15 of 15was then evaluated by investigating the extent of apoptosis
induction by TUNEL staining in vivo (Figure 6C). In
agreement with in vitro signal expression results, HepG2
tumors considerably induced apoptosis protein expression
in mice treated with GGMPN. We also found that the Au
concentration in the nude mice injected with GGMPN
was significantly higher in tumor tissues than in the other
groups (Figure 6D). In summary, these results demon-
strated that the delivery of miR-122 by the multifunctional
effect of GGMPN provided a novel and effective strategy
to induce apoptosis and inhibit the growth of tumor cells.
Conclusions
Taken together, GGMPN has the following advantages:
(1) due to the high proportion of specific surface area of
graphene, the drug loading capacity of the nanocompos-
ite is greatly improved; (2) the properties of graphene
and gold nanoparticles result in low toxicity; (3) bound
P-gp antibody and FA has preferred targeting ability;
(4) the nano-composite can increase the permeability
of a drug-resistant cancer cell membrane, promote the
gold particle uptake by the cancer cells and enhance intra-
cellular drug accumulation; (5) the nano-composites have
good properties to promote drug-resistant cancer cell
apoptosis; (6) the nano-composites attach to tumor cells,
resulting in efficient photothermal therapy for killing can-
cer cells; and (7) the nano-composites allow specific fluor-
escent bio-marking of the tumors.
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